N-nitrosamine impurities

N-nitrosamine impurities analysis includes all main impurities identified by the health authorities as well as nitrosations of APIs. Default screening limits originally established at 0.03ppm have been gradually improved, with our current sensitivity levels having reached 0.1ppb. The list below shows currently available nitrosamines, but new ones can be added upon client request:

  • N-Nitrosodimethylamine (NDMA)
  • N-Nitrosodiethylamine (NDEA)
  • N-Nitrosodisopropylamine (NDIPA)
  • N-Nitroso ethylisopropylamine (NEIPA)
  • N-Nitroso-n-methyl-4-aminobutyric acid (NMBA)
  • N-Nitrosopyrrolidine (NPYR)
  • N-Nitrosodi-n-butylamine (NDBA)
  • N-Nitroso Morpholine (NMOR)
  • N-Nitrosodiethanolamine (NDELA)
  • N-nitrosopiperazine (NPIP)
  • N-nitroso-N-methylaniline (NMA)
  • N-nitrosoethylmethylamine (NMEA)
  • N-Nitrosodiphenylamine (NDPhA)
  • N-nitrosodi-n-propylamine (NDPA)
  • N-nitroso-N-methylaniline (NMPA)
  • 1-Methyl-4-nitrosopiperazine (MeNP)
  • di-n-nitrosopiperazine (DNPZ)
  • 2-Nitroso-octahydrocyclopentapyrrole
  • N-nitroso-piperazine (MNPZ)
  • N-nitroso-vareni_cline (NNV)
  • 7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3- a]pyrazine

Kymos offers a competitive service owing to its dedicated nitrosamines team, significant sample analysis capabilities and two back-up methods available: Liquid chromatography-mass spectrometry (LC-MS/MS) Agilent 6490 Triple Quadrupole plus a Headspace Gas Chromatography (HS-GC-MS) Agilent 7890 with a 5977 Single Quadrupole limits. Our nitrosamines team continuously adapts our service to comply with new request of the Regulatory Agencies:

Lower LoQs: Initial 0.03ppm default limits were lowered to our current sensitivity of 0.1ppb

New LoQs based on acceptable intake (AI) and API maximum daily dose (MDD) depending on quantification type: ≤ 30% if the quantitative testing is performed to justify skip testing or ≤ 10% if performed to justify omission of specification.

Acceptable intake limits (AI): FDA recommends the following limits for nitrosamines listed below:

Analytical Experts
Nitrosamines HPLC determination

Kymos offers a competitive service owing to its dedicated nitrosamines team, significant sample analysis capabilities and two back-up methods available: Liquid chromatography-mass spectrometry (LC-MS/MS) Agilent 6490 Triple Quadrupole plus a Headspace Gas Chromatography (HS-GC-MS) Agilent 7890 with a 5977 Single Quadrupole limits. Our nitrosamines team continuously adapts our service to comply with new request of the Regulatory Agencies:

  • Lower LoQs: Initial 0.03ppm default limits were lowered to our current sensitivity of 0.1ppb
  • New LoQs based on acceptable intake (AI) and API maximum daily dose (MDD) depending on quantification type: ≤ 30% if the quantitative testing is performed to justify skip testing or ≤ 10% if performed to justify omission of specification.
  • Acceptable intake limits (AI): FDA recommends the following limits for nitrosamines listed below:
nitrosamines GC-MS
NitrosamineAI Limit (ng/day)
NDMA96.0
NDEA26.5
NMBA96.0
NMPA26.5
NDIPA26.5
EIPNA26.5
MeNP26.5
NDBA26.5
NMOR127.0
NN37.0

Related Services

Quality Control of Biologics and Biosimilars

Complex characterization projects for innovative biologics and comparison of biosimilars.

Quality Control of Small Molecules

Analytical tests for APIs, excipients, intermediate products, finished products, packaging materials and process environment samples.

Batch Testing and Batch Release

KYMOS and PHARMAPROGRESS are GMP certified and we have a partial manufacturer authorization for Quality Control purposes.

Stability Studies

Full ICH studies and on-going stability programmes at different storage conditions.

DO YOU NEED MORE INFORMATION OR A QUOTE?

EU Sites

Kymos Group

Barcelona
Spain

Prolytic

Frankfurt
Germany

Pharmaprogress

Ancona
Italy

EU Offices

Paris
France

Basel
Switzerland

Milano
Italy